Loading…
Chinese maker of point-of-care rapid diagnostic tests, including pregnancy, drug-of-abuse and infectious-disease test kits.
Chinese maker of point-of-care rapid diagnostic tests, including pregnancy, drug-of-abuse and infectious-disease test kits.
Sells over-the-counter test strips through pharmacies, e-commerce and distributors at low unit prices, so volume and brand recognition matter more than price. Covid tests lifted sales during the pandemic, and routine tests such as pregnancy kits carry the business over the long run.
In one line: A Chinese Abbott/Quidel for rapid diagnostics.
Moat: narrow (brand, distribution, scale). Largest domestic rapid-test brand with broad export distribution across 100+ countries.
Headquarters: Guangzhou, China · Employees: 2,443
Size Guangzhou Wondfo Biotech (300482.SZ) is a China Health Care company (Biotechnology) with a market value of $1.14B, the 2056th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥16.41 on 6 Nov 2026.
Performance Over six months the shares fell 10.3%, against -10.8% for the median peer and -16.4% for the China market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue fell 23.6% over the last twelve months (peer median +1.4%); the operating margin is -2.5% (peer median -12.4%).
Valuation It trades at 31.0× forward earnings against a peer median of 29.4× (4th most expensive of 8).
Price implies For today's price to make sense, revenue must grow about 16% a year for seven years (Req g). Recent delivered growth is -6%, so the hurdle is +22 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 6.6 points below its cost of capital (9.4% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.97B | CN¥2.08B | CN¥3.06B | CN¥2.76B | CN¥5.67B |
| Revenue growth | — | -32% | +11% | -51% | — |
| Gross profit | CN¥1.19B | CN¥980M | CN¥1.75B | CN¥1.52B | CN¥2.72B |
| EBITDA | n/a | CN¥135M | CN¥862M | CN¥738M | CN¥1.60B |
| Net income | -CN¥62.9M | -CN¥63.0M | CN¥562M | CN¥488M | CN¥1.20B |
| Free cash flow | CN¥769M | CN¥207M | CN¥100M | -CN¥44.5M | CN¥1.16B |
| Capital expenditure | CN¥205M | CN¥305M | CN¥318M | CN¥433M | CN¥583M |
| Total debt | CN¥63.7M | CN¥654M | CN¥777M | CN¥614M | CN¥788M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Guangzhou Wondfo Biotech 300482.SZ | $1.14B | -10% | -24% | -2% | 31.0× | 16.4% |
| Innovita Biological Technology 688253.SS | $1.02B | -4% | -28% | 11% | 103.0× | 42.9% |
| Abbott Laboratories ABT | $190B | +30% | +10% | 14% | 18.8× | 5.6% |
| QuidelOrtho QDEL | $734M | -1% | -5% | -2% | 12.0× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300482.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.6% | -5.6% | 8th highest of 21 |
| 6-month return | -10.3% | -10.8% | 10th highest of 21 |
| Distance from 52-week high | -37.6% | -38.3% | 11th highest of 21 |
| Revenue growth (TTM) | -23.6% | +1.4% | 3rd lowest of 14 |
| Operating margin | -2.5% | -12.4% | 7th highest of 14 |
| Forward P/E | 31.0× | 29.4× | 4th most expensive of 8 |
| Growth the price implies (Req g, 7 yrs) | 16.4% | 9.9% | 2nd most demanding of 7 |
| Growth delivered (Del g) | -5.8% | -2.3% | 4th highest of 7 |
| Hurdle (Req g minus delivered) | +22.2 pp | +12.3 pp | 3rd most demanding of 7 |
| ROIC minus cost of capital | -6.6 pp | -2.3 pp | 3rd lowest of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Guangzhou Wondfo Biotech 300482.SZ | China | $1.14B | -10% | -24% | -2% | 31.0× | 16.4% | -5.8% |
| Rapport Therapeutics RAPP | United States | $1.17B | -36% | n/a | -838% | n/a | n/a | n/a |
| Daan Gene 002030.SZ | China | $1.11B | -9% | +1% | -81% | n/a | 5.7% | -32.3% |
| UroGen Pharma URGN | United States | $1.21B | -16% | +159% | -12% | 13.9× | n/a | n/a |
| Janux Therapeutics JANX | United States | $1.08B | +24% | +5,367% | -598% | n/a | n/a | n/a |
| COMPASS Pathways Plc Sponsored ADR CMPS | United States | $1.22B | -13% | n/a | n/a | n/a | n/a | n/a |
| Vor Biopharma VOR | United States | $1.22B | +17% | n/a | n/a | n/a | n/a | n/a |
| Akums Drugs and Pharmaceuticals AKUMS.NS | India | $1.22B | +34% | +18% | 10% | 27.0× | 15.8% | +9.9% |
| Duality Biotherapeutics 9606.HK | Hong Kong | $1.23B | -60% | -5% | -181% | n/a | n/a | n/a |
| SpyGlass Pharma SGP | United States | $1.24B | +58% | n/a | n/a | n/a | n/a | n/a |
| Inhibrx Biosciences INBX | United States | $1.24B | -37% | -100% | n/a | n/a | n/a | n/a |
| Verastem VSTM | United States | $1.02B | +72% | +3,996% | -183% | n/a | n/a | n/a |
| Innovita Biological Technology 688253.SS | China | $1.02B | -4% | -28% | 11% | 103.0× | 42.9% | -16.6% |
| Liaoning Chengda Biotechnology 688739.SS | China | $1.28B | -10% | -9% | 0% | 46.2× | 8.8% | -7.0% |
| Changchun BCHT Biotechnology 688276.SS | China | $1.00B | -11% | +2% | -29% | n/a | n/a | n/a |
| Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZ | China | $995M | -11% | 0% | 22% | 23.6× | 11.1% | +2.3% |
| Alto Neuroscience ANRO | United States | $987M | +4% | n/a | n/a | n/a | n/a | n/a |
| Mineralys Therapeutics MLYS | United States | $1.36B | -48% | n/a | n/a | n/a | n/a | n/a |
| China Animal Husbandry Industry 600195.SS | China | $960M | -17% | +1% | 2% | 35.8× | 6.6% | +4.4% |
| Jade Biosciences JBIO | United States | $958M | -42% | n/a | n/a | n/a | n/a | n/a |
| Pacific Shuanglin Bio-pharmacy 000403.SZ | China | $1.38B | -19% | +1% | 10% | 29.4× | n/a | n/a |